ArticleJournal of cancer research and clinical oncology2020

Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.

Taiki Hakozaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.